Post Menopausal Osteoporosis - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 86
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PCC1BAD49D2EN
Leaflet:

Download PDF Leaflet

Post Menopausal Osteoporosis - Pipeline Review, H2 2017
Post Menopausal Osteoporosis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2017, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 4, 2, 1 and 7 respectively.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Post Menopausal Osteoporosis - Overview
Post Menopausal Osteoporosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
Amgen Inc
Enteris BioPharma Inc
GL Pharm Tech Corp
Intas Pharmaceuticals Ltd
Ipsen SA
Lupin Ltd
Luye Pharma Group Ltd
NIBEC
Oncobiologics Inc
Paras Biopharmaceuticals Finland Oy
Sermonix Pharmaceuticals LLC
Post Menopausal Osteoporosis - Drug Profiles
(cholecalciferol + risedronate sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abaloparatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcitonin DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lasofoxifene tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romosozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teriparatide biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Post Menopausal Osteoporosis - Dormant Projects
Post Menopausal Osteoporosis - Discontinued Products
Post Menopausal Osteoporosis - Product Development Milestones
Featured News & Press Releases
Oct 13, 2017: Radius Health to Present First Health Economics Data on TYMLOS (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2017
Sep 11, 2017: EVENITY (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine
Sep 10, 2017: Radius Health Presents Positive Data for TYMLOS (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR 2017 Annual Meeting
Sep 08, 2017: Amgen Highlights Prolia (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting
Sep 08, 2017: UCB highlights latest EVENITY research at the American Society for Bone and Mineral Research Annual Meeting
Sep 01, 2017: Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research (ASBMR) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVExtend Trials for TYMLOS (abaloparatide) Injection
Jul 21, 2017: Radius Health Announces that the CHMP Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Jul 16, 2017: Amgen And UCB Provide Update On Regulatory Status Of EVENITY (romosozumab) In The US
Jun 14, 2017: New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis
May 24, 2017: Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS in Postmenopausal Women with Osteoporosis
May 21, 2017: Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY (Romosozumab) In Postmenopausal Women With Osteoporosis
Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Apr 07, 2017: Osteoporosis drug found safe in long-term trial
Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies
Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Post Menopausal Osteoporosis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Post Menopausal Osteoporosis - Pipeline by Amgen Inc, H2 2017
Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc, H2 2017
Post Menopausal Osteoporosis - Pipeline by GL Pharm Tech Corp, H2 2017
Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H2 2017
Post Menopausal Osteoporosis - Pipeline by Ipsen SA, H2 2017
Post Menopausal Osteoporosis - Pipeline by Lupin Ltd, H2 2017
Post Menopausal Osteoporosis - Pipeline by Luye Pharma Group Ltd, H2 2017
Post Menopausal Osteoporosis - Pipeline by NIBEC, H2 2017
Post Menopausal Osteoporosis - Pipeline by Oncobiologics Inc, H2 2017
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017
Post Menopausal Osteoporosis - Pipeline by Sermonix Pharmaceuticals LLC, H2 2017
Post Menopausal Osteoporosis - Dormant Projects, H2 2017
Post Menopausal Osteoporosis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Post Menopausal Osteoporosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Amgen Inc
Enteris BioPharma Inc
GL Pharm Tech Corp
Intas Pharmaceuticals Ltd
Ipsen SA
Lupin Ltd
Luye Pharma Group Ltd
NIBEC
Oncobiologics Inc
Paras Biopharmaceuticals Finland Oy
Sermonix Pharmaceuticals LLC
Skip to top


Ask Your Question

Post Menopausal Osteoporosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: